On February 19, 2026 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will highlight recent updates and progress in Azitra’s pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults; and ATR-01 targeting ichthyosis vulgaris, which is undergoing IND-enabling studies.
Details are as follows:
Event:
BIO Investment & Growth Summit
Date & Time:
Monday, March 2, 2026, 2:15 PM ET
Location:
Ballroom 2C, Eden Roc Miami Beach Hotel
Presenter:
Travis Whitfill, Chief Operating Officer
Registration:
During the events, members of Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the Company’s clinical development strategy, recent corporate achievements, and anticipated milestones.
(Press release, Azitra, FEB 19, 2026, View Source [SID1234662781])